Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Sauerstofftherapie bei Kindern und Jugendlichen mit Down-Syndrom und obstruktiver Schlafapnoe (DOSA)

25. September 2026 aktualisiert von: Susan Redline, Brigham and Women's Hospital

Randomisierte Kontrollstudie zur Sauerstofftherapie bei Kindern und Jugendlichen mit Down-Syndrom und obstruktiver Schlafapnoe

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

This will be a randomized, single-blind 6-month Phase-2 clinical trial that compares the impact of oxygen therapy during sleep on measures of cognition, behavior, quality of life, cardiac structure and function, and sleep in children with Down Syndrome(DS) with moderate to severe obstructive sleep apnea.

The proposed study will involve participation of children and their caregivers. Children will be recruited from each site's sleep clinics and laboratories, Down syndrome clinics and otolaryngology clinics. Community recruitment will be coordinated with local Down Syndrome Associations.

Children who agree to participate in the study will be screened for eligibility based on history, physical examination, and review of medical records including history of congenital heart disease and Pulmonary Hypertension (PHTN), and use of Continuous Positive Airway Pressure (CPAP). Children eligible for the study are those with persistent obstructive apnea after adenotonsillectomy or children with obstructive sleep apnea without adenotonsillar hypertrophy or in situations when parents refuse adenotonsillectomy.. The enrollment PSG eligibility will be determined by central scoring of either a research Polysomnography (PSG). In addition to an oxygen titration PSG, which determines responsiveness to oxygen, participants will be asked to wear a wrist actigraph and undergo neurocognitive testing, echocardiography, physical examination, anthropometry, and venipuncture. Caregivers will complete questionnaires to assess their child's emotional, physical, social, and school functioning, sleep quality; child's behavior and cognitive function, and will complete a sleep diary that is used concurrently with their child's use of a wrist actigraph. The latter includes caregiver completion of the "Behavior Rating Inventory of Executive Function" (BRIEF2), a co-primary outcome.

At 3 months, caregivers will complete the BRIEF2. At 6 months, all baseline studies and a PSG will be repeated.

At baseline, demographic data will be collected, including information on residential address (for use in geocoding).

Studientyp

Interventionell

Einschreibung (Geschätzt)

230

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • California
      • Los Angeles, California, Vereinigte Staaten, 90027
        • Rekrutierung
        • Children's Hospital of Los Angeles
        • Kontakt:
        • Hauptermittler:
          • Sally Ward, MD
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Rekrutierung
        • University of Michigan, Ann Arbor Hospital
        • Kontakt:
        • Hauptermittler:
          • Ronald Chervin, MD
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45229
        • Rekrutierung
        • Cincinnati Children's Hospital Medical Center
        • Hauptermittler:
          • Raouf Amin, MD
        • Kontakt:
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • Rekrutierung
        • Rainbow Babies and Children's Hospital, Case Medical Center
        • Kontakt:
        • Hauptermittler:
          • Sally Ibrahim, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia
        • Kontakt:
        • Hauptermittler:
          • Christopher Cielo, MD
    • Virginia
      • Norfolk, Virginia, Vereinigte Staaten, 23507
        • Rekrutierung
        • East Virginia Medical Center
        • Kontakt:
        • Hauptermittler:
          • Cristina Baldassari, MD
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98105

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

5 Jahre bis 18 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Ages 5.0 to 17.9 years at the time of screening

  2. Children with OSA and obstructive apnea hypopnea index (OAHI) ≥5/hour.

  3. Absence of clinically significant hypoxia defined as oxygen saturation <88% for 5 minutes or episodic desaturation to 60% as these levels would otherwise identify children eligible to routinely receive oxygen.

  4. Favorable response to oxygen therapy (allowing randomization) will be defined as follows:

    1. Oxygen saturation nadir >92% and
    2. Decrease in obstructive index < 5 / hour or by > 50% from screening PSG
    3. Reaching an optimum oxygen flow which is defined as the flow that achieves the lowest level of AHI with maximum CO2 level less than 65 mmHg observed for 5 consecutive minutes and or an increase in CO2 by less than 15 points above baseline. The above criteria are observed while the patient spends a minimal of 30 minutes in the supine position and at least one cycle of rapid eye movement (REM) sleep.
    4. Oxygen flow required does not exceed 3.0 LPM and does not exceed a FiO2 > 40 %.
  5. Willingness to comply with all study procedures and available for duration of study.

  6. At baseline the participant attempts to perform the neuropsychological tests

Exclusion Criteria:

  1. Current CPAP use with documented compliance(> 4 hrs/ night; > 70% of nights).
  2. Oxygen saturation < 90% at rest during wakefulness.
  3. Chronic daytime or nighttime use of supplemental oxygen.
  4. Smoker in the child's bedroom.
  5. Unrepaired congenital heart disease.
  6. Moderate to severe pulmonary hypertension requiring treatment with oxygen and or pulmonary vasodilator.
  7. Unable to participate in a PSG.
  8. Individuals who develop alveolar hypoventilation with oxygen as previously defined.
  9. Other severe chronic diseases determined by their provider as making them poor study candidates.
  10. Enrolled or planning to enroll in another study that may conflict with protocol requirements or confound results in this trial.
  11. Documented clinically significant untreated hypothyroidism
  12. Children with adenotonsillar hypertrophy who are candidates for adenotonsillectomy and parents agree to the surgery.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Oxygen plus supportive care (OXT)

Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Active nocturnal oxygen concentrator

Kein Eingriff: Supportive care (SC)

Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score
Zeitfenster: Baseline and 6 months

Change from baseline in the Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score (BRIEF2wm). The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 months
Differential Ability Scales - 2nd Edition (DAS-II) T-score.
Zeitfenster: Baseline and 6 months

Change from baseline in the Differential Ability Scales - 2nd Edition (DAS-II) recognition of pictures (DAS2RoP) T-score. The score ranges from 10-90. A higher score is a better outcome.

Baseline and 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score
Zeitfenster: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score. The score ranges from 0-64. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score
Zeitfenster: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score. The score ranges from 0-30. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score
Zeitfenster: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score. The score ranges from 0-34. A higher score is a better outcome.

Baseline and 6 Months
Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score
Zeitfenster: Baseline and 6 Months

Change from baseline in Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score. The score ranges from 0-38. A higher score is a better outcome.

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed
Zeitfenster: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)
Zeitfenster: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)

Baseline and 6 Months
Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score
Zeitfenster: Baseline and 6 Months

Change from baseline in Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score. Range-N/A

Baseline and 6 Months
Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score
Zeitfenster: Baseline and 6 Months

Change from baseline in Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score. The score ranges from 0-135. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate)
Zeitfenster: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).
Zeitfenster: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)
Zeitfenster: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)

Baseline and 6 Months
KIDSCREEN-27 T-score
Zeitfenster: Baseline and 6 Months

Change from baseline in KIDSCREEN-27 T-score, including domains of: physical well-being; psychological well-being; autonomy and parent relations; social support and peers; school environment. Range-N/A

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score
Zeitfenster: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score. The score ranges from 28.7-85.6. A higher score is a worse outcome.

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score
Zeitfenster: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score. The score ranges from 37.9-86.6. A higher score is a worse outcome.

Baseline and 6 Months
Presence of right ventricular hypertension
Zeitfenster: Baseline and 6 Months

Presence of right ventricular hypertension as measured by tricuspid regurgitation continuous wave peak velocity (defined as a ratio of pulmonary artery pressure / systolic arterial pressure (PAP/SAP) >1/3); interventricular septal flattening as measured by eccentricity index (defined as systolic ratio of >1.25)

Baseline and 6 Months
Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score
Zeitfenster: Baseline and 6 Months

Change from baseline of Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score. The score ranges from 0-128. A higher score is a better outcome.

Baseline and 6 Months
Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score
Zeitfenster: Baseline and 6 Months

Change from baseline in Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score (if unable to complete Wechsler Intelligence Scale 5th edition Cancellation test). The score ranges from 0-96. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain.
Zeitfenster: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain.
Zeitfenster: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain.
Zeitfenster: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
7-day actigraphy measurement of sleep efficiency
Zeitfenster: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep efficiency

Baseline and 6 Months
7-day actigraphy measurement of time wake after sleep onset
Zeitfenster: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of time wake after sleep onset

Baseline and 6 Months
7-day actigraphy measurement of sleep fragmentation
Zeitfenster: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep fragmentation

Baseline and 6 Months
7-day actigraphy measurement of total sleep duration
Zeitfenster: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of total sleep duration

Baseline and 6 Months
Polysomnography (PSG) AHI parameter
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) AHI parameter. The score ranges from 0- >40. A higher score is a worse outcome.

Baseline and 6 Months
Polysomnography (PSG) percentage time of O2 <90 % parameter
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) percentage time of O2 <90 % parameter

Baseline and 6 Months
Polysomnography (PSG) sleep apnea associated hypoxic burden parameter
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) sleep apnea associated hypoxic burden, parameter

Baseline and 6 Months
Polysomnography (PSG) end-tidal CO2 level, parameter
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) end-tidal CO2 parameter.

Baseline and 6 Months
Polysomnography (PSG) -based measure of sleep stages
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of sleep stages. Range- N/A

Baseline and 6 Months
Polysomnography (PSG) -based measure of EEG power bands
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of EEG power bands

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle morphology
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle morphology

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle numbers
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle numbers

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle density
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle density

Baseline and 6 Months
Polysomnography (PSG) -based measure of slow wave oscillations
Zeitfenster: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of slow wave oscillations

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)

Baseline and 6 Months
Left ventricular diastolic function as measured by E wave deceleration time
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by E wave deceleration time

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time

Baseline and 6 Months
Left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration

Baseline and 6 Months
Left ventricular diastolic function as measured by Left atrial volume
Zeitfenster: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Left atrial volume

Baseline and 6 Months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

24. Oktober 2023

Primärer Abschluss (Geschätzt)

30. November 2027

Studienabschluss (Geschätzt)

30. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

17. August 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. September 2023

Zuerst gepostet (Tatsächlich)

21. September 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren